Intellia Therapeutics, Inc.

How big is Intellia Therapeutics, Inc.?

As of Jun 18, Intellia Therapeutics, Inc. has a market capitalization of 992.33 million, with net sales of 45.57 million and a net profit of -525.91 million over the latest four quarters. The company reported shareholder's funds of 871.96 million and total assets of 1,191.02 million as of Dec 24.

Market Cap: As of Jun 18, Intellia Therapeutics, Inc. has a market capitalization of 992.33 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Intellia Therapeutics, Inc. reported net sales of 45.57 million and a net profit of -525.91 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 871.96 million and total assets of 1,191.02 million.

What does Intellia Therapeutics, Inc. do?

Intellia Therapeutics, Inc. is a small-cap genome editing company specializing in CRISPR/Cas9 technology for therapeutic development. As of March 2025, it reported net sales of $17 million and a net loss of $114 million, with a market cap of approximately $992.33 million.

Overview: <BR>Intellia Therapeutics, Inc. is a genome editing company focused on developing therapeutics using the CRISPR/Cas9 technology, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 17 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -114 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 992.33 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.60 <BR>Return on Equity: -62.93% <BR>Price to Book: 1.27<BR><BR>Contact Details: <BR>Address: 40 Erie St Ste 130, CAMBRIDGE MA: 02139-4254 <BR>Tel: ['1 857 2856200', '1 857 7061612'] <BR>Fax: 1 302 6555049 <BR>Website: http://www.intelliatx.com/

Should I buy, sell or hold Intellia Therapeutics, Inc.?

Who are in the management team of Intellia Therapeutics, Inc.?

As of March 2022, the management team of Intellia Therapeutics, Inc. includes Dr. John Leonard as CEO and Independent Chairman Dr. Frank Verwiel, along with several independent directors.

As of March 2022, the management team of Intellia Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Frank Verwiel, who serves as the Independent Chairman of the Board.<BR>- Dr. John Leonard, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Frederick Cohen, who is an Independent Director.<BR>- Mr. John Crowley, who is also an Independent Director.<BR>- Ms. Caroline Dorsa, serving as an Independent Director.<BR>- Dr. Jean-Francois Formela, who is an Independent Director.<BR>- Dr. Jesse Goodman, who is an Independent Director.<BR><BR>In summary, the management team comprises key figures including the CEO, Dr. John Leonard, and several independent directors led by Dr. Frank Verwiel as the Chairman.

Is Intellia Therapeutics, Inc. overvalued or undervalued?

As of March 14, 2017, Intellia Therapeutics, Inc. is considered a risky investment due to overvaluation and poor financial metrics, including a negative P/E ratio of -2.7230 and a 3-year return of -75.48%, despite a recent short-term stock gain of 41.07%.

As of 14 March 2017, the valuation grade for Intellia Therapeutics, Inc. moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued given its negative performance metrics and ratios. Key ratios include a Price to Book Value of 1.07, an EV to Sales ratio of 8.19, and a ROCE of -169.74%, which highlight significant operational challenges.<BR><BR>In comparison to its peers, Intellia's P/E ratio is notably negative at -2.7230, while BridgeBio Pharma, Inc. has a P/E of -14.1231, and CRISPR Therapeutics AG stands at -13.2694, indicating that Intellia is not alone in facing valuation difficulties, but it still lags behind in terms of relative performance. Despite a strong short-term stock return of 41.07% over the past week compared to the S&P 500's 1.05%, the longer-term outlook remains bleak, with a 3-year return of -75.48% against the S&P 500's 70.41%.

Is Intellia Therapeutics, Inc. technically bullish or bearish?

As of September 19, 2025, Intellia Therapeutics, Inc. shows a mildly bullish trend with positive MACD and Bollinger Bands, despite a mildly bearish On-Balance Volume, having outperformed the S&P 500 recently but underperformed over the past year.

As of 19 September 2025, the technical trend for Intellia Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, indicating a positive momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, supporting the upward trend. Daily moving averages are also bullish, reinforcing the current stance. However, the monthly On-Balance Volume is mildly bearish, suggesting some caution.<BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 over the past week and month, with returns of 49.18% and 64.07% respectively, compared to the S&P 500's 1.22% and 3.95%. However, over the longer term, the stock has underperformed the index, with a 1-year return of -21.12% versus the S&P 500's 16.64%.<BR><BR>Overall, the current technical stance is mildly bullish, driven by positive indicators in MACD, Bollinger Bands, and moving averages, despite some bearish signals from the OBV.